Clinical Trial Update: Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on ambrisentan (Letairis) for sarcoidosis-associated pulmonary hypertension; study phases 2 and 3 completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension
• Sarcoidosis

Drugs mentioned

• Ambrisentan (Ambrisentan)
• LETAIRIS (ambrisentan)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Sarcoidosis, Pulmonary Hypertension | Phase 2, Phase 3 | Status: COMPLETED